Compounded GLP-1 Medications: What You Need to Know Before Choosing One

Compounded GLP-1 Medications: What You Need to Know Before Choosing One

By Dr. Onikepe Adegbola, MD PhD

Compounded GLP-1 medications have become one of the most discussed topics in obesity medicine. Patients who can't access brand-name semaglutide or tirzepatide due to cost, insurance denial, or supply shortages are turning to compounding pharmacies as an alternative. As a physician who prescribes GLP-1 medications daily at Mochi Health, I need patients to understand what compounded GLP means, where the real risks sit, and how to make an informed decision.

This article isn't going to tell you compounded GLP-1 is always dangerous. It also won't tell you it's equivalent to the brand-name product. The truth sits in between, and the details matter.

Key Takeaways

• Compounded GLP-1 refers to semaglutide or tirzepatide prepared by compounding pharmacies, not manufactured by the brand-name pharmaceutical companies
• Compounding is legally permitted when the FDA determines a drug shortage exists for the brand-name product
• Quality, purity, and potency vary significantly between compounding pharmacies
• Compounded versions are not FDA-approved and don't undergo the same testing as Ozempic or Wegovy
• The regulatory environment is shifting rapidly; what's legal today may change within months

What Is Compounded GLP-1 Medication?

Compounded GLP-1 refers to semaglutide or tirzepatide that has been prepared by a compounding pharmacy rather than manufactured by Novo Nordisk (Ozempic, Wegovy) or Eli Lilly (Mounjaro, Zepbound). Compounding pharmacies create customized medications by combining pharmaceutical-grade ingredients according to a physician's prescription.

Compounding itself is a longstanding, legitimate practice in pharmacy. It predates mass pharmaceutical manufacturing. When a patient needs a specific dose, formulation, or combination that isn't commercially available, compounding fills that gap. Dermatology, pediatrics, and hormone therapy rely on compounding routinely.

The GLP-1 compounding market exploded for a specific reason: shortage. When demand for Ozempic and Wegovy outstripped supply in 2022-2023, the FDA placed semaglutide on its drug shortage list. Under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies can legally produce copies of drugs that are on the shortage list.

This is the legal basis. Without the shortage designation, compounding a patented molecule like semaglutide would be far more legally complex. The regulatory framework around compounded GLP medications continues to shift, and patients should stay informed about current status.

How Compounded GLP-1 Differs from Brand-Name Products

The active molecule in compounded semaglutide is the same amino acid sequence as brand-name semaglutide. In theory. In practice, several factors create meaningful differences.

Manufacturing Standards

Novo Nordisk manufactures Ozempic and Wegovy in FDA-inspected facilities under Current Good Manufacturing Practice (cGMP) regulations. Every batch undergoes potency testing, sterility testing, endotoxin testing, and stability testing. The manufacturing process is validated with extensive quality controls.

Compounding pharmacies operate under different regulatory frameworks depending on their designation:

• 503A pharmacies compound based on individual patient prescriptions. They're regulated primarily by state boards of pharmacy. FDA oversight is limited.
• 503B outsourcing facilities can compound without individual prescriptions and are subject to more FDA oversight, including facility inspections. They must follow cGMP-like standards, though not identical to those required of traditional pharmaceutical manufacturers.

The quality gap between the best 503B facilities and poorly managed 503A pharmacies is enormous. Some compounding pharmacies produce high-quality products with rigorous testing. Others cut corners. The patient often has no way to distinguish between them.

Purity and Potency Concerns

Independent testing of compounded semaglutide products has revealed concerning variability. Some samples contained less active ingredient than labeled. Others contained impurities. A few contained incorrect salt forms (semaglutide sodium rather than semaglutide base, which affects dosing calculations).

This isn't a theoretical concern. The FDA has issued multiple warning letters to compounding pharmacies producing GLP-1 products. Some products tested positive for bacterial contamination. When you inject a contaminated product subcutaneously, you risk local infection, abscess formation, or systemic infection.

Formulation Differences

Brand-name Ozempic uses a specific formulation with excipients designed to optimize stability, absorption kinetics, and shelf life. The multi-dose pen delivery system ensures accurate dosing. Compounded versions may use different excipients, different concentrations, and different delivery methods (often vials requiring the patient to draw up doses with a syringe).

Drawing up your own subcutaneous injection from a vial introduces a source of dosing error that pre-filled pens eliminate. Patients who've never handled syringes may under- or over-dose. Air bubbles, incorrect needle gauge, and improper storage all create additional variables.

The Risk-Benefit Calculation

Here's where I'll give you my honest clinical perspective.

Brand-name GLP-1 medications are superior products from a quality assurance standpoint. Full stop. If you can access and afford them, they're the better choice. Insurance coverage, manufacturer savings programs, and patient assistance programs should all be explored before turning to compounding.

But medicine operates in the real world. The cash price for Wegovy exceeds $1,300 per month. Many insurance plans don't cover weight loss medications. Savings programs have income requirements or coverage gaps. For patients who would otherwise have zero access to these medications, a well-sourced compounded product from a reputable 503B facility may be a reasonable alternative.

The key word is "reputable." How do you evaluate that?

What to Look for in a Compounding Pharmacy

1. 503B outsourcing facility designation. These facilities face more regulatory scrutiny than 503A pharmacies.
2. Third-party testing. Ask whether each batch is tested by an independent laboratory for potency, purity, sterility, and endotoxins. Request certificates of analysis.
3. State board of pharmacy licensure. Verify the pharmacy is licensed and has no disciplinary actions.
4. Physician oversight. Your prescribing physician should be monitoring your response, adjusting doses, and ordering appropriate lab work regardless of whether you're using brand-name or compounded product.
5. Transparent ingredient sourcing. Reputable pharmacies can tell you where their semaglutide raw material comes from and provide documentation.

Nutritional Support Matters Regardless of Your GLP-1 Source

Whether you're taking brand-name Ozempic, Wegovy, or a compounded GLP-1 preparation, the metabolic demands on your body are similar. Reduced caloric intake, altered nutrient absorption from delayed gastric emptying, and rapid tissue changes during weight loss create nutritional gaps that need addressing.

In my practice, I see patients on both brand-name and compounded GLP medications develop the same nutritional deficiencies: protein insufficiency, micronutrient depletion, and digestive complaints from altered GI motility. The medication source doesn't change the nutritional challenge.

Casa de Sante GLP-1 supplements are formulated specifically for patients on GLP-1 therapy, regardless of the product source. The gut-gentle, low-FODMAP formulations address the digestive and nutritional challenges that accompany GLP-1 receptor agonist treatment.

The Regulatory Future of Compounded GLP-1

The regulatory picture is changing. The FDA periodically reassesses the drug shortage list. When semaglutide comes off the shortage list (Novo Nordisk has been working aggressively to increase manufacturing capacity), the legal basis for compounding it becomes significantly narrower.

Patients currently using compounded GLP-1 should have a plan for this transition. Options may include:

• Transitioning to brand-name product if it becomes accessible or affordable
• Exploring insurance appeals with updated clinical documentation
• Considering alternative GLP-1 medications that may have better insurance coverage
• Working with your physician on a maintenance strategy that may involve different dosing or medication combinations

This is not a situation where patients should be caught off guard. If you're on compounded semaglutide, discuss the regulatory timeline with your prescriber now.

Frequently Asked Questions

Is compounded GLP-1 the same as Ozempic?

Compounded semaglutide contains the same active molecule as Ozempic. However, it's not the same product. The manufacturing process, quality controls, excipients, and delivery system differ. Compounded products have not undergone the FDA approval process that validates safety, efficacy, and consistency. Think of it as the same ingredient prepared in a different kitchen with different quality standards.

Is compounded semaglutide legal?

As of this writing, compounding semaglutide is legal when it's on the FDA drug shortage list and when prepared by a licensed compounding pharmacy with a valid patient prescription. The legality depends on the shortage designation. If semaglutide comes off the shortage list, the legal basis changes significantly. Check the current FDA drug shortage database for the latest status.

Why is compounded GLP-1 so much cheaper?

Brand-name pricing reflects research and development costs, clinical trial expenses, FDA approval costs, marketing, and profit margins. Compounding pharmacies don't bear these costs. They purchase raw materials and prepare the formulation. The cost difference is significant: compounded semaglutide typically runs $200-500 per month versus $1,300+ for brand-name products without insurance.

Can my doctor prescribe compounded semaglutide?

Any licensed physician can write a prescription for compounded semaglutide, just as they can for any compounded medication. Whether they choose to depends on their clinical judgment, the regulatory environment, and their assessment of the compounding pharmacy's quality. Some physicians are comfortable with this. Others aren't. Both positions are defensible.

What are the biggest risks of compounded GLP-1?

The primary risks are inconsistent potency (getting more or less drug than intended), contamination (bacterial or endotoxin), and incorrect formulation. These risks are higher with unverified pharmacies. Choosing a 503B outsourcing facility with third-party batch testing significantly reduces but doesn't eliminate these risks. Physician monitoring remains important regardless of product source.